Takeda Pharma unveils new TOURMALINE-AL1 Phase-3 clinical trial update
Category: #health  By Mateen Dalal  Date: 2019-06-07
  • share
  • Twitter
  • Facebook
  • LinkedIn

Takeda Pharma unveils new TOURMALINE-AL1 Phase-3 clinical trial update

· The company announced that the clinical trial failed to fulfil the first of the two preestablished endpoints.

· Citing the result of the analysis, Takeda Pharma has decided to permanently halt the trial.

Takeda Pharmaceutical Company Ltd. (Takeda Pharma), a renowned Japanese pharmaceutical company, has reportedly released a new update on its ongoing Phase-3 TOURMALINE-AL1 clinical trial in individuals suffering from refractory or relapsed systemic light-chain amyloidosis.

Reports cite, the clinical trial failed to fulfil the first of the two preestablished endpoints, wherein an assessment of treatment through a combination of dexamethasone & NINLAROTM (ixazomib).

According to a report by Financial Post, the combination treatment failed to demonstrate any substantial improvement in the patients overall hematologic response as compared to a physician’s preferred standard of care.

The Head of Oncology Therapeutic Area Unit at Takeda, Phil Rowlands, Ph.D., stated that while the company is disappointed with the outcome of the trial, it still aims to maximize its own learnings from the trial and further share any findings with the community with the intention that it would help improve care for individuals that are living with the debilitating disease.

The trial was one of the biggest studies to be ever conducted for systemic light-chain AL amyloidosis, demonstrating the company’s dedication in finding a cure for the rare disease with a patient population that is conventionally difficult to enroll.

Meanwhile, the company remains optimistic regarding NINLARO as an individual entity and would continue to investigate the candidate in patients across the sequence of multiple-myeloma care.

While an Independent Data Monitoring Committee (IDMC) has not raised any concerns about NINLARO’s safety, patients are still encouraged to approach their respective study investigators to address any queries.

According to reports, citing the result of the dexamethasone & NINLARO combination treatment analysis, Takeda Pharma has decided to permanently halt the clinical trial.

Source Credit: https://www.takeda.com/newsroom/newsreleases/2019/takeda-provides-update-on-tourmaline-al1-phase-3-trial/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Google’s business intelligence platform Looker collabs with Tableau
Google’s business intelligence platform Looker collabs with Tableau
By Mateen Dalal

Google Cloud Platform has recently revealed that its business intelligence platform, Looker has been integrated with Tableau, empowering users of both the platforms to benefit from the different features offered by each. For starters, Google Cloud a...

HR tech firm Personio ropes in $270 million in latest financing round
HR tech firm Personio ropes in $270 million in latest financing round
By Mateen Dalal

Personio, a HR software provider targeting small and medium sized businesses, has attained a $270 million investment in the wake of high demand for its services. With the latest Series E round of funding, Personio's valuation roses to $6.3 billi...

New Zealand prepares to deal with potential surge in COVID-19 cases
New Zealand prepares to deal with potential surge in COVID-19 cases
By Mateen Dalal

New Zealand is preparing for an increase in Covid-19 cases after registering 94 new infections over the weekend, with pandemic modelers predicting that if the government continues on its present path, new cases would rapidly exceed 100 per day. Epid...